Search Clinical Trials ?


Trials Open: 23
Cancer Type: Lung
Protocol No.Title
15-LUN-99-JCASR vs. SAbR in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
EA8143Nivolumab vs. Observation in Localized RCC Undergoing Nephrectomy
MCC-11-MULTI-12Carfilzomib + Irinotecan after Platinum Chemotherapy for Recurrent Small Cell Lung Cancer
MCC-13-0280-P1HPut It Out & Keep It Off: An Appalachian CBPR Smoking & Weight Control Program
MCC-13-MULTI-13-KCTN-1301Optimization of Smoking Cessation Strategies Concurrent w/Treatment of Tobacco Related Malignancies
MCC-14-0929-F3RPerfusion-Induced Hyperthermia for Metastatic Non-Small Cell Lung Carcinoma
MCC-14-MULTI-14Effects of Hydroxychloroquine on PAR-4 Levels for Resectable Solid Tumors
MCC-16-0304-P3KMCC-16-0304-P3K: Connecting Appalachians to Lung Cancer Screening: Leveraging Social Networks to Reduce Lung Cancer
MCC-16-HN-29Cisplatin + radiation in SCCHN and Correlation with Oxidative Stress Markers
MCC-16-MULTI-18Genomic Testing for Patients with Refractory Cancer to Determine Treatment
MCC-16-MULTI-19Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
MCC-16-MULTI-21Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension
MCC-17-BS-01Kentucky LEADS Collaborative: Lung Cancer Survivorship Care Program
NCI-CALGB-30610/RTOG-0538Thoracic Radiotherapy Regimens + Cisplatin + Etoposide for Small Cell Lung Cancer
NCI-CIRB-A081105-ALCHALCHEMIST substudy: Erlotinib vs Placebo in Resected EGFR Mutant NSCLC
NCI-CIRB-A151216-ALCHAdjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
NCI-CIRB-E4512ALCHEMIST substudy: Crizotinib vs Placebo for Resected NSCLC with Alk Fusion
NCI-CIRB-EA5142NCI-CIRB-EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ALCHEMIST)
NCI-CIRB-LAO-MA036-9903AZD9291 + Navitoclax for EGFR-mutant Non-Small Cell Lung Cancer Resistant to EGFR Kinase Inhibitor
NCI-CIRB-LAO-NCI-9149Molecular Profiling-Based Targeted Therapy in Advanced Solid Tumors (MPACT)
NCI-CIRB-S1400Master Protocol for Second Line Therapy Squamous Cell Lung Cancer
NCI-CIRB-S1403NCI-CIRB-S1403: A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)